36 results
8-K
EX-3.2
THRX
Theseus Pharmaceuticals Inc
14 Feb 24
Completion of Acquisition or Disposition of Assets
10:44am
of Directors resulting from death, resignation, retirement, disqualification, removal from office or other cause may be filled by the affirmative vote … have been duly elected and qualified, or until such person’s earlier death, disqualification, resignation or removal. Any number of offices may be held
SC TO-T/A
EX-99
Concentra Merger Sub II, Inc.
14 Feb 24
Third party tender offer statement (amended)
10:35am
(a) upon death of a Holder by will or intestacy; (b) pursuant to a court order; (c) by operation of law (including by consolidation or merger … the death, incompetence, bankruptcy or liquidation of any Holder and shall be binding on any successor thereto, and (ii) shall survive the delivery
SC TO-T/A
EX-99
THRX
Theseus Pharmaceuticals Inc
30 Jan 24
Third party tender offer statement (amended)
8:23am
) upon death of the holder by will or intestacy; (ii) pursuant to a court order; (iii) by operation of law (including a consolidation or merger … , until their respective successors are duly elected and qualified, or their earlier death, resignation or removal. Theseus will request each director
SC TO-T
EX-99
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Third party tender offer statement
8:51am
Agreements.”
MAY I TRANSFER MY CONTINGENT VALUE RIGHTS?
The CVRs will not be transferable except: (i) upon death of the holder by will or intestacy … successors are duly elected and qualified, or their earlier death, resignation or removal. Theseus will request each director of Theseus immediately prior
SC TO-T
EX-99
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Third party tender offer statement
8:51am
not be affected by, and shall survive the death or incapacity of the undersigned, and any obligation of the undersigned hereunder shall be binding upon … to accept for payment any Shares tendered hereby.
The undersigned understands that the CVRs will not be transferable except: (i) upon death
8-K
EX-2.1
e8nkytaz rizyzw2o2
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
EX-99.2
g9nkzc nv
25 May 23
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
5:04pm
PRE 14A
154j6841m q6q2mwnrxs
14 Apr 23
Preliminary proxy
9:00am
DEF 14A
skz62q5tcxp cjw79c5
25 Apr 22
Definitive proxy
4:30pm
10-K
6jatx5y3kjbcdr p6w94
10 Mar 22
Annual report
7:23am
10-Q
EX-3.2
jg9 grn3yj5xjll
15 Nov 21
Quarterly report
7:36am
10-Q
31dil8
15 Nov 21
Quarterly report
7:36am
10-Q
EX-3.1
rn3ef czzs
15 Nov 21
Quarterly report
7:36am
424B4
jfccmq9o0 i9ifdtbvu
7 Oct 21
Prospectus supplement with pricing info
5:03pm
S-1/A
EX-10.15
4tnvun1x6s1lbfuzuj
30 Sep 21
IPO registration (amended)
6:33am
S-1/A
EX-3.4
h26bs3dy
30 Sep 21
IPO registration (amended)
6:33am
S-1/A
EX-10.4
kuh3ous
30 Sep 21
IPO registration (amended)
6:33am